Uveal Melanoma and Brachytheraphy: Long-term Outcomes. | NCT04577742 | Trialant

Uveal Melanoma and Brachytheraphy: Long-term Outcomes. | NCT04577742 | Trialant

Arms/Interventions Module

Interventions

Name	Type	Description	Arm Group Labels	Other Names
106 Ruthenium plaque brachytherapy	Radiation	All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
To evaluate long-term outcomes in patients underwent brachytherapy for uveal melanoma	To investigate the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival	Mean follow-up was 4 years (3 months-9 years)

Condition Browse Module